The size of the North America Injectable Drug Delivery Market was valued at USD 1579.70 million in 2022. It is further estimated to be growing at a CAGR of 11.09% and worth USD 2672.69 million by 2027.
The market for injectable medication delivery would expand due to the growing need and demand for patient compliance with treatment. The rising demand for vaccines, insulin, human growth hormone, and many other modern medicines used to treat cancer and other chronic diseases, as well as rising levels of investment in advanced technology, spending on pharma medicines, and growth in the biologics market, will likely accelerate the growth of the injectable drug delivery market in North America region. Because of the effective and focused medication release and low side effects on the body, the Injectable drug delivery market is primarily driven by rising occurrences of chronic diseases in this region. In addition, smart devices that measure dosage and time and additional features like reminders and automated dose changes can help enhance treatment adherence and compliance even further.
The North American injectable drug delivery market achieves a wide scope of development and lucrative outcome via innovations, technical advancements, and marketing of new products driven by major manufacturers. Furthermore, there is a growing emphasis on product safety, efficacy, and patient-friendliness. The injectable medication delivery market would expand in the next few years due to the need for improved technologies to meet the rising demand for regular injectable medicines to treat chronic diseases. Cancer and heart disease were responsible for around 48 percent of all fatalities. It was also revealed that almost half of all individuals in the United States had one or more chronic conditions, with one out of every four having more than two. The rising prevalence of chronic diseases is expected to contribute to the growth of the injectable drug delivery technology market in the forecast period, given the high adoption rate of injectable drug delivery devices among the population suffering from diabetes and heart-related disorders.
With the rising number of needle-related injuries and infections, individuals are becoming less willing to utilize injections, restricting the growth of the North American injectable drug delivery technology market. In addition, the industry is also facing challenges by the growing use of alternate medication delivery techniques and safety issues connected with injections.
This research report on the North America Injectable Drug Delivery Market has been segmented and sub-segmented into the following categories:
By Device Type:
By Formulation:
By Therapeutic use:
By End User:
By Country:
Geographically, Because of the growing diagnosis and treatment of chronic illnesses in these areas, North America accounted for the largest proportion of the worldwide injectable drug delivery market. Increased R&D expenditure and rising healthcare spending are some of the reasons driving the injectable medication delivery market in these regions. Because of the rising prevalence of cardiovascular illnesses, the expanding elderly population, and the strong presence of industry players in that area, the United States injectable drug delivery technology market held the highest market share in North America in 2020. A significant driver driving regional market expansion is the increased use of new injectable medication delivery systems among diabetes, cancer, and other autoimmune disease patients in North America. Furthermore, these injectables' convenience and therapeutic advantages are driving demand, allowing North America to capture the largest share of the global market.
KEY MARKET PLAYERS:
Some of the major companies dominating the North America Injectable drug delivery market profiled in the report are Antares Pharmaceuticals Ltd, Baxter International, Becton Dickinson Company, Elcam Medical, Eli Lily and Company, Unilife Corporation, and West Pharmaceutical Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Device Type
5.1.1 Introduction
5.1.2 Self-injection Devices
5.1.3 Conventional Devices
5.1.4 Y-o-Y Growth Analysis, By Device Type
5.1.5 Market Attractiveness Analysis, By Device Type
5.1.6 Market Share Analysis, By Device Type
5.2 Formulation
5.2.1 Introduction
5.2.2 Conventional Drug Delivery
5.2.3 Novel Drug Delivery
5.2.4 Y-o-Y Growth Analysis, By Formulation
5.2.5 Market Attractiveness Analysis, By Formulation
5.2.6 Market Share Analysis, By Formulation
5.3 Therapeutic Use
5.3.1 Introduction
5.3.2 Autoimmune Disorders
5.3.3 Hormonal Disorders
5.3.4 Oncology
5.3.5 Y-o-Y Growth Analysis, By Therapeutic Use
5.3.6 Market Attractiveness Analysis, By Therapeutic Use
5.3.7 Market Share Analysis, By Therapeutic Use
5.4 End-user
5.4.1 Introduction
5.4.2 Hospitals
5.4.3 Homecare Settings
5.4.4 Research Institutes
5.4.5 Clinical Laboratories
5.4.6 Other
5.4.7 Y-o-Y Growth Analysis, By End-user
5.4.8 Market Attractiveness Analysis, By End-user
5.4.9 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Device Type
6.1.3.3 By Formulation
6.1.3.4 By Therapeutic Use
6.1.3.5 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Device Type
6.1.4.3 By Formulation
6.1.4.4 By Therapeutic Use
6.1.4.5 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Device Type
6.1.5.3 By Formulation
6.1.5.4 By Therapeutic Use
6.1.5.5 By End-user
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alkermes Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bend Research
8.3 BIND Biosciences Inc.
8.4 Endocyte
8.5 Genentech Inc.
8.6 MicroCHIPS Inc.
8.7 Pearl Therapeutics Inc.
8.8 Polymer Factory
8.9 Presage Bioscience
8.10 QLT Inc.
8.11 UCB Group.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
